Research ArticleClinical Investigations
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
Ali Afshar-Oromieh, Henrik Hetzheim, Clemens Kratochwil, Martina Benesova, Matthias Eder, Oliver C. Neels, Michael Eisenhut, Wolfgang Kübler, Tim Holland-Letz, Frederik L. Giesel, Walter Mier, Klaus Kopka and Uwe Haberkorn
Journal of Nuclear Medicine November 2015, 56 (11) 1697-1705; DOI: https://doi.org/10.2967/jnumed.115.161299
Ali Afshar-Oromieh
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
Henrik Hetzheim
3Division of Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany
Clemens Kratochwil
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
Martina Benesova
4Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
Matthias Eder
4Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
Oliver C. Neels
4Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
Michael Eisenhut
4Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
Wolfgang Kübler
5Division of Radiation Protection and Dosimetry, German Cancer Research Center, Heidelberg, Germany; and
Tim Holland-Letz
6Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany
Frederik L. Giesel
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
Walter Mier
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
Klaus Kopka
4Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
Uwe Haberkorn
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
2Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 11
November 1, 2015
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
Ali Afshar-Oromieh, Henrik Hetzheim, Clemens Kratochwil, Martina Benesova, Matthias Eder, Oliver C. Neels, Michael Eisenhut, Wolfgang Kübler, Tim Holland-Letz, Frederik L. Giesel, Walter Mier, Klaus Kopka, Uwe Haberkorn
Journal of Nuclear Medicine Nov 2015, 56 (11) 1697-1705; DOI: 10.2967/jnumed.115.161299
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
Ali Afshar-Oromieh, Henrik Hetzheim, Clemens Kratochwil, Martina Benesova, Matthias Eder, Oliver C. Neels, Michael Eisenhut, Wolfgang Kübler, Tim Holland-Letz, Frederik L. Giesel, Walter Mier, Klaus Kopka, Uwe Haberkorn
Journal of Nuclear Medicine Nov 2015, 56 (11) 1697-1705; DOI: 10.2967/jnumed.115.161299
Jump to section
Related Articles
Cited By...
- Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
- The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics
- Evaluation of 134Ce/134La as a PET Imaging Theranostic Pair for 225Ac {alpha}-Radiotherapeutics
- Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study
- From Concept to Regulatory Drug Approval: Lessons for Theranostics
- Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors
- Bringing VISION to Nuclear Medicine: Accelerating Evidence and Changing Paradigms with Theranostics
- Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
- Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
- Radiolabeling of PSMA-617 with 89Zr: A Novel Use of DMSO for Radiochemical Yield Enhancement and Preliminary Small-Animal PET Results
- Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer
- Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy
- 68Ga-PSMA PET/CT Combined with PET/Ultrasound-Guided Prostate Biopsy Can Diagnose Clinically Significant Prostate Cancer in Men with Previous Negative Biopsy Results
- Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer
- Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine
- Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer
- Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes
- Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer
- Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics
- Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands
- Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade
- Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window
- PET-CT Cancer Imaging
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- 18F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution
- PSMA Ligands for PET Imaging of Prostate Cancer
- Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- 68Ga-PSMA-PET/CT Has a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease
- 68Ga or 18F for Prostate Cancer Imaging?
- Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models
- Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
- Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
- Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer
- The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
- Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis